WuXi XDC's first-half results and backlog beat expectations; JPMorgan raises target price to HK$91

Overview

The report reviews WuXi XDC's 1H26 results, focusing on order growth, project mix, margins, progress in commercial projects, and capacity construction. JPMorgan believes that near-term pressure from consolidation and capacity ramp-up is manageable, while complex conjugate projects and late-stage manufacturing projects will support medium- to long-term growth. It therefore maintains its Overweight rating and raises its target price.

Core views

WuXi XDC's 1H26 operating performance exceeded JPMorgan's expectations, with growth driven by demand for both ADCs and the broader XDC category. Revenue reached RMB 37.01 hundred million, increasing 37.0% YoY at actual exchange rates and 41.5% at constant exchange rates; gross profit increased 40.6% YoY to RMB 13.71 hundred million, with gross margin rising from 36.1% to 37.0%; adjusted net profit attributable to shareholders increased 37.4% YoY to RMB 10.27 hundred million, with adjusted net margin rising from 27.7% to 27.8%. Service backlog was approximately US$2.0 billion, up 50.4% YoY; total backlog including potential milestone payments was approximately US$2.2 billion, up 62.2% YoY. US orders continued to grow well despite adverse exchange-rate effects, leading the report to conclude that geopolitical concerns have not yet visibly affected orders. The company did not raise its guidance and continues to expect FY26 revenue growth of more than 35% in US dollar terms, while maintaining its target of a 30%-35% revenue CAGR from 2026E to 2030E. The project mix is shifting toward businesses with greater technical complexity, providing an important foundation for medium-term margin improvement. In 1H26, the company signed 51 new integrated chemistry, manufacturing, and controls (iCMC) projects, of which more than 75% involved new targets, novel payload-linker systems, or innovative conjugate formats; approximately 16% were bispecific ADC projects and 22% were XDC projects, including dual-payload ADCs, antibody-oligonucleotide conjugates (AOCs), antibody-peptide conjugates (APCs), and T-cell engager ADCs. The consolidation of BioDlink and the ramp-up of the Singapore site are expected to continue weighing on FY26 gross margin, but JPMorgan believes that a richer and more complex project portfolio can partially offset the impact and drive gross-margin improvement in FY27. It forecasts gross margins of 36.0% in FY26E, 36.1% in FY27E, and 36.2% in FY28E. Longer-term margin expansion will depend on rising contributions from late-stage clinical, process performance qualification (PPQ), and commercial manufacturing projects. As of June 30, 2026, the company had 21 PPQ projects, approximately half of which came from overseas customers, and had completed delivery of 27 PPQ components. Management expects to execute more than 30, 45, and 60 PPQ components in 2026, 2027, and 2028, respectively, while expecting 4-6, 7-10, and 12-15 biologics license application (BLA) submissions from the company's project pipeline in those years. By 2030, the company aims for XDCs and other novel conjugates and commercial manufacturing to each contribute 20% of total revenue. The report believes this transition will improve revenue visibility and generate operating leverage and higher-quality earnings through greater capacity utilization and project scale. Capacity expansion is generally progressing as scheduled. The seven existing production lines in Wuxi continue to operate at high utilization rates, while XPLM1L2, DP5, and DP6 are expected to obtain GMP release by late 2026 or early 2027, 1H27, and 1H28, respectively. The Singapore mAb/BCM3 and DP4 production lines obtained GMP release in August 2026, while the BCM4 site is scheduled for release by the end of 2026. The Jiangyin XPLM2 facility is designed for annual capacity of 3-5 tonnes, and its payload-linker capacity is expected to reach approximately five times the current Wuxi level. The group expects total capital expenditure of RMB 8.0 billion from 2026 to 2030, consistent with guidance from the previous earnings call. JPMorgan believes these new facilities are essential for fulfilling the backlog and advancing late-stage and commercial projects. Based on the 1H26 results and backlog growth of more than 50% YoY, JPMorgan raised its FY26E-FY28E revenue forecasts by 0%-2%, its FY29E-FY33E revenue forecasts by 4%-9%, and its FY26E-FY28E gross-margin forecasts by a modest 0-0.5 percentage points. Following these adjustments, adjusted net profit forecasts increased by 2%-10% for FY26E-FY28E and by 2% for FY29E-FY33E; the FY26E adjusted net profit forecast was raised from RMB 18.12 hundred million to RMB 19.72 hundred million, an increase of 8.8%. The report forecasts FY26E, FY27E, and FY28E revenue of RMB 80.97 hundred million, RMB 108.61 hundred million, and RMB 143.52 hundred million, respectively; adjusted net profit of RMB 19.72 hundred million, RMB 30.98 hundred million, and RMB 40.10 hundred million; and adjusted earnings per share of RMB 1.49, RMB 2.34, and RMB 3.02. FCFF for the same periods is forecast at RMB 9.37 hundred million, RMB 19.14 hundred million, and RMB 28.34 hundred million, respectively. Based on 2025 revenue, WuXi XDC ranked first in both the global and Chinese CRDMO markets for ADCs and other bioconjugates. JPMorgan believes the company's capabilities across multiple technology platforms and its integrated service system make it a major beneficiary of ADC market growth, with further potential to improve margins and market share. The report uses a DCF valuation, extends the target-price horizon by 12 months to December 2027, and raises the target price from HK$76 to HK$91; key assumptions are a 3.0% terminal growth rate and an 11.3% weighted average cost of capital. The rating remains Overweight. The report also notes that the company's share price has risen by more than 40% over the past 30 days, compared with gains of 11% for the Hang Seng China Enterprises Index, 27% for WuXi AppTec, and 32% for WuXi Biologics over the same period. Consequently, subsequent share-price performance may depend more heavily on securing new commercial projects.

Analysis framework

JPMorgan first uses 1H26 revenue, margins, and backlog to assess operating performance and demand strength. It then evaluates future revenue quality and the margin trajectory based on project complexity, PPQ stages, BLA submissions, and the share of commercial manufacturing. Next, it assesses delivery capacity by considering the GMP release schedules and capital-expenditure plans for each site, and updates its revenue, gross-margin, net-profit, and free-cash-flow forecasts accordingly. Finally, the report incorporates the revised cash-flow forecasts into a DCF model and determines the target price using a terminal growth rate and WACC.

Methodology notes

• Valuation methodologyDCF discounted cash flow

  DCF valuation

  The report discounts future cash flows to present value and uses a 3.0% terminal growth rate and an 11.3% WACC to derive a target price of HK$91 as of December 2027.

• Company fundamentals and financial frameworkFree cash flow analysis

  FCFF forecast

  The report forecasts free cash flow to the firm of RMB 9.37 hundred million, RMB 19.14 hundred million, and RMB 28.34 hundred million for FY26E through FY28E, respectively. This measures the cash available to the company's capital providers after capital expenditure and provides the basis for the DCF valuation.

• Company fundamentals and financial framework

  Project-stage funnel analysis

  The report assesses the pace at which projects convert from R&D to commercialization and their impact on revenue visibility, margins, and earnings quality by examining the complexity of newly signed iCMC projects, the number of PPQ projects and components executed, BLA submissions, and the share of commercial manufacturing.

• Industry analysis framework

  Capacity ramp-up and utilization analysis

  The report tracks utilization rates, GMP release dates, and incremental capacity at the Wuxi, Singapore, and Jiangyin facilities to assess whether the company can fulfill rapidly growing orders and achieve economies of scale.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi XDC (2268.HK)

  The report considers the company a major beneficiary of growth in the ADC and other bioconjugate markets and maintains its Overweight rating.

  Strengths

  Ranked first by 2025 revenue in both the global and Chinese CRDMO markets for ADCs and other bioconjugates; possesses capabilities across technology platforms, an integrated service system, a strong backlog, and a growing number of late-stage and commercial projects.

  Weaknesses

  The consolidation of BioDlink and the ramp-up of Singapore capacity are expected to create margin pressure in FY26, while capacity expansion also requires continued substantial capital expenditure.

  Comparison

  The share price has risen by more than 40% over the past 30 days, outperforming the 11% gain in the Hang Seng China Enterprises Index, the 27% gain in WuXi AppTec, and the 32% gain in WuXi Biologics.

  Risks

  Tighter regulatory requirements, competition from overseas CDMOs, customer product-development failures, and losses or failures in biotechnology investments.

Key data

• 1H26 revenueRMB 37.01 hundred millionUp 37.0% YoY at actual exchange rates and 41.5% YoY at constant exchange rates
• 1H26 gross profitRMB 13.71 hundred millionUp 40.6% YoY, with gross margin increasing from 36.1% to 37.0%
• 1H26 adjusted net profit attributable to shareholdersRMB 10.27 hundred millionUp 37.4% YoY, with adjusted net margin increasing from 27.7% to 27.8%
• Service backlogApproximately US$2.0 billionUp 50.4% YoY
• Total backlog including potential milestone paymentsApproximately US$2.2 billionUp 62.2% YoY
• Company revenue growth targetOver 35% in FY26; 30%-35% CAGR from 2026E-2030EBoth are in US dollar terms; the company did not raise its guidance following these results
• New iCMC projects signed in 1H2651More than 75% involve new targets, novel payload-linkers, or innovative conjugate formats; 16% are bispecific ADCs and 22% are XDCs
• PPQ projects as of June 30, 202621Approximately half are from overseas customers, and 27 PPQ components have been delivered
• PPQ component execution targetsMore than 30 in 2026, 45 in 2027, and 60 in 2028Used to measure the pace of progress for late-stage and commercial projects
• BLA submission targets4-6 in 2026, 7-10 in 2027, and 12-15 in 2028From the company's project pipeline
• 2030 revenue-mix targetXDCs and other novel conjugates and commercial manufacturing to each account for 20% of total revenueThe report believes this will improve revenue visibility and operating leverage
• Capital expenditure from 2026-2030RMB 8.0 billionConsistent with guidance from the previous earnings call
• FY26E adjusted net profit forecastRMB 19.72 hundred millionPreviously RMB 18.12 hundred million, raised by 8.8%
• FY26E-FY28E revenue forecastsRMB 80.97 hundred million, RMB 108.61 hundred million, and RMB 143.52 hundred millionCorresponding to YoY growth of 36.2%, 34.1%, and 32.1%
• FY26E-FY28E adjusted net profit forecastsRMB 19.72 hundred million, RMB 30.98 hundred million, and RMB 40.10 hundred millionFollowing the model update, FY26E-FY28E forecasts were raised by 2%-10% overall
• Key DCF assumptionsTerminal growth rate of 3.0%, WACC of 11.3%Used to calculate the HK$91 target price as of December 2027

Impact & implications

The report believes that WuXi XDC's order growth not only supports near-term revenue but also improves medium- to long-term revenue visibility and earnings quality through rising shares of complex projects, PPQ, and commercial manufacturing. The consolidation of BioDlink and the ramp-up of the Singapore site will weigh on FY26 margins, but the complex project mix can partially offset this effect, with margin improvement expected to become more evident in FY27. On-schedule capacity deployment is critical to converting the backlog into revenue, while the recent significant share-price increase makes the acquisition of new commercial projects an important driver of subsequent performance.

Risks

• The industry is highly regulated, and stricter regulatory requirements may affect the company's operations.
• Competition from overseas CDMOs may weaken the company's market share or profitability.
• Customer product-development failures could damage the company's reputation and affect its ability to attract or retain customers.
• Losses or failures in biotechnology investments may weigh on the company's performance.

What to watch

• Monitor whether the company can secure new commercial projects; the report believes subsequent share-price performance may depend on this following the recent sharp increase.
• Monitor whether FY26 revenue growth in US dollar terms can meet the company's target of more than 35% and whether a 30%-35% CAGR can be achieved from 2026E to 2030E.
• Monitor the impact of BioDlink's consolidation and the Singapore site's ramp-up on FY26 margins, as well as whether the complex project mix can drive gross-margin improvement in FY27.
• Monitor whether the production lines in Wuxi, Singapore, and Jiangyin can obtain GMP release as scheduled and successfully increase utilization rates.
• Monitor the number of PPQ components executed, the number of BLA submissions, and progress in increasing the share of commercial manufacturing revenue from 2026 to 2028.